

## SUBJECT INDEX VOLUME 6

Absorption .....	1053	functional chemokine receptors in .....	463
ACE inhibitors (ACEI) .....	491	therapeutic target in .....	463
angiotensin receptor blocker combinations		Allergic inflammation .....	463
with .....	491	CCR8 in .....	463
clinical applications of .....	494	pathogenesis of .....	463
ACEA 1011/1021 .....	1194	Alzheimer's disease .....	1075
preparation of .....	1194	associated molecules in .....	1075
ACEA 1416 .....	1194	intracellular A $\beta$ 42 pathogenesis in .....	1077
preparation of .....	1194	intracellular amyloid $\beta$ -protein .....	1075
Acetylcholinesterase reactivators .....	269	P53 activation in .....	1076
development of .....	276	P53-dependent neuronal apoptosis in .....	1078
length/rigidity of .....	272	pathogenesis of .....	1075
oxime group in .....	274	therapeutic strategies to .....	1078
quaternary nitrogen in .....	271	$\beta$ -Amino acids .....	296
structural requirement of .....	269	into biologically active peptides .....	296
structure of .....	270	of $\alpha$ -amino- $\beta$ -hydroxy acids .....	299
Adenosine-to-inosine RNA editing .....	1213	of $\alpha$ -hydroxy- $\beta$ -amino acids .....	301
increasing diversity of .....	1215	2-(4-Aminophenyl) benzothiazole .....	633
mechanism of .....	1215	against tumor cell lines .....	633
predications of .....	1213	as selective pharmacophore .....	633
role of genome .....	1215	biotransformation of .....	636
Adiponectin .....	651,1331	chemistry of .....	633
AMPK pathway of .....	1332	mechanism study of .....	635
APPLI signaling of .....	1331	mechanistic action of .....	633
as novel pharmacological target .....	1331	metabolism of .....	636
caspase signaling of .....	1335	physicochemical study of .....	636
cross talk of .....	1335	structure activity relationship of .....	634
function of .....	651	Amphotericin B (AmB) .....	153
in insulin resistance .....	653	effects on immune functions .....	155
in non-alcoholic fatty liver disease .....	651	encapsulated with lipid components .....	159
in obesity .....	653	formulations approved for human use .....	157
insulin signaling pathways of .....	1335	mode of action of .....	154
MAPK pathways of .....	1333	oral treatment by .....	160
mode of action of .....	652	particulate formulations of .....	158
NF- $\kappa$ B signaling of .....	1334	pharmacokinetics of .....	156
oriented therapies .....	654	resistance to .....	157
pathophysiological implications .....	651	selective binding to ergosterol .....	154
peroxisome proliferators-activated receptor		solubilization attempts to .....	159
(PPAR) pathways of .....	1334	toxicity of .....	155
receptors for .....	652,1331	Anadamide .....	258
regulation gene expression of .....	1336	degradation of .....	258
role of cyclooxygenase-2 (Cox-2) .....	1134	inhibitors of inactivation of .....	260
signaling pathway of .....	1331	synthesis of .....	258
structure of .....	651	therapeutic applications of inhibitors of .....	263
ADME .....	1053	Androgen receptor .....	49
in drug preclinical development .....	1053	Angiotensin-(1-7) .....	603
in medium/high-throughput screening .....	1053	as novel renin-angiotensin system mediator .....	603
Akt/P13K inhibitors .....	1127	in cardiovascular system .....	603
biological activity of .....	1127	in male reproductive system .....	607
glucose-based inositol analogues as .....	1133	in renal system .....	605
inositolphosphate-based inhibitors as .....	1131	in renin angiotensin system in liver .....	607
phosphatidylinositol ether lipid analogues as .....	1129	therapeutic potential of .....	603
synthesis of .....	1127	Angiotensin II receptor blockers (ARBs) .....	835,839
Allergic disease .....	463	as PPAR- $\gamma$ ligand .....	841
CCR8 in .....	463	in prostate cancer .....	839

Angiotensin receptor blockers (ARB) .....	491	mechanisms of resistance of .....	178
clinical applications of .....	494	protein modification as target of .....	185
Antibacterial .....	1276	redox metabolism as target for .....	163
assays for .....	1279	Anti-MDR agent .....	1387
ATP synthase inhibitors as .....	1280	structural requirement for anti-calmodulin	
discovery of .....	1276	antagonists as .....	1387
genomic technologies for .....	1276	Anti-mitotic drugs .....	1145
novel compounds as .....	1280	anti-calmodulin activity of .....	1145
peptide deformylase inhibitors as .....	1280	Antioxidants .....	235,265,305,567
screening of .....	1279	ABTS method for .....	306
systems biology for .....	1277	alkaline DMSO method for .....	307
Anticancer agents .....	131,533,1135,1137,1145	as novel agents for asthma .....	235
ansamycins as .....	1138	automated radical absorbance capacity assay	
BCL-2 family members as .....	1035	for .....	308
caspases as .....	1038	$\beta$ -carotene bleaching method for .....	306
competitive inhibitors of pyrophosphates as .....	138	cytochrome C reduction method for .....	307
ether lipids as .....	533	deoxyribose assay for .....	307
Hsp90 inhibitors as .....	1137	DPPH assay for .....	306,310
IAPs as .....	1039	electron spin trapping method for .....	308
in antiparasitic chemotherapy .....	131	<i>ex vivo</i> methods for .....	310
<i>in vitro</i> cytotoxicity of .....	1148	Gibb's reagent for .....	307
<i>in vivo</i> antitumor activity against		hydrogen peroxide scavenging for .....	308
transplantable tumor .....	1151	hydroxyl radical scavenging for .....	307
inhibitors of polyamine synthesis as .....	139	hydroxylamine auto oxidation method for .....	307
kinase inhibitors/synthetic sphingolipid		<i>in vitro</i> methods for .....	305
analogues as .....	135	<i>in vivo</i> methods for .....	311
macrolide as .....	1139	natural coumarins as .....	270
non-phosphorus cationic glycerolipids in .....	533	nitric oxide scavenging for .....	308
proteasome inhibitors as .....	137	phenazine methosulphate-NADH system for .....	307
protein kinase inhibitors as .....	133	<i>p</i> -nitroso dimethylaniline (pNDA) bleaching	
purine-scaffold derivatives as .....	1139	method for .....	307
pyrazoles as .....	1139	PPAR agonists and .....	567
shepherdin as .....	1140	pyrogallol auto oxidation method for .....	307
targeting microtubular systems .....	1145	riboflavin photo-oxidation method for .....	307
tyrosine kinase inhibitors as .....	135	screening methods for .....	305
Anti-coagulant drugs .....	612	superoxide anion scavenging of .....	307
from plants .....	612	synthetic coumarins as .....	266
Anti-hyperglycemic .....	349	tyrosine nitration assay for .....	309
AGH inhibitory assay system for .....	350	xanthine-xanthine oxidase system for .....	307
effect of natural IAGH inhibitors .....	354	Antiplatelet drugs .....	612,719
inhibition of glucosf production in GUT by .....	351	aspirin as .....	719
Antihypertensive drugs .....	838	collagen receptors as target of .....	724
Anti-influenza agents .....	429	cyclooxygenase inhibitor as .....	719
active site of .....	432	endothelial ecto-adenosine phosphatase as	
containing furan scaffold .....	440	target of .....	724
neuraminidase inhibitors as .....	444	from capsicum genus .....	615
neuroamidase inhibitors as .....	431	from plants .....	612
polyvalent neurminidase inhibitors as .....	443	glycoprotein IIB/IIIA antagonists as .....	722
sialic acid as .....	431	inhibitors of vWF-GPIb activation as target of ....	724
with neuraminidase as target .....	429	mechanisms of action of .....	719
Antimalarials .....	163,177	pituitary adenylyl cyclase-activating peptide	
antioxidant defense as target of .....	190	as target of .....	725
coenzyme/prosthetic group metabolism as		targets for .....	719,723
target of .....	183	thienopyridines as .....	720
DNA replication/transcription as target of .....	187	thrombin receptors as target of .....	724
drug targets of .....	178	$\alpha$ 1-Antiproteinase .....	309
energy metabolism as target of .....	178	inactivation of .....	309
hemoglobin digestion as target of .....	189	Antisense phosphorothioates .....	319
mechanisms of action of .....	177	cyclic phosphoramidite approaches of .....	321

oxathiaphospholane approach for .....	320	Breast cancer cells .....	331
stereocontrolled synthesis of .....	319	gene expression of matrix macromolecules	
Antisense strategy .....	319	by .....	331
Anti-viral therapy .....	557	Calcium channels .....	747
Apoptosis .....	699	biotransformation of .....	751
anti-apoptotic signaling pathways for .....	701	photostability of .....	751
extrinsic pathway in .....	699	structure-activity relationships of .....	750
in neurodegenerative diseases .....	704	Calcium/reperfusion injury .....	1084
intrinsic pathway in .....	699	Calmodulin .....	1152,1383
pathways in .....	699	antagonists as anti-cancer agents .....	1385
pro-apoptotic signaling pathways for .....	701	as target of bisindoles .....	1152
regulation of .....	701	drug binding of .....	1153
related diseases .....	704	in cancer .....	1384
Arachidonoylglycerol .....	260	Calmodulin-KAR-2 complex .....	1153
degradation of .....	260	3D structure of .....	1153
inhibitors of inactivation of .....	260	Cancer .....	401,639,827,885,897,1044,1101,1137,1258
synthesis of .....	260	antibiotics against .....	643
therapeutic applications of inhibitors of .....	263	broad spectrum inhibitors targeting	
Ashtma .....	335,339	angiogenesis for .....	1107
airway hyperresponsiveness/remodelling in .....	339	celecoxib for .....	828
airway inflammation in .....	344	cisplatin in .....	1140
airway wall thickening in .....	344	COX inhibitors in .....	830
antioxidant treatment in .....	238	epothilones for .....	885
cysteine in .....	238	estrogens in .....	897
endogenous antioxidant defenses in .....	235	genistein in .....	401
GSH in .....	238	glycosidase in .....	1044
NAC/OTC in treatment of .....	239	glycosidase inhibitors in .....	1045
oxidative stress in .....	237	Hsp90 in .....	1137
reactive oxygen species (ROS) in .....	235	hyperleptinemia in .....	900
Aurora kinase inhibitors .....	890	leptin in .....	897
		ligand-based design of kinase inhibitors for .....	1107
		novobiocin in .....	1140
B/K class CPG-ODN .....	258	obesity in .....	900
as vaccine adjuvant for infection/cancer .....	258	platinum compounds against .....	640
9-BBN .....	3	pofecoxib for .....	828
ZED versions of .....	3	polo-like kinase inhibitors for .....	892
BCL-XL .....	979	polyamines against .....	644
1,4-Benzodiazepine-2-ones .....	53	prevention of .....	401
1,4-Benzodiazepine-2,3-diones .....	59	prostanoids in .....	829
1,4-Benzodiazepine-2,5-diones .....	57	quinazolines in .....	1103
1,5-Benzodiazepine .....	60	quinones against .....	646
1,5-Benzodiazepine-2-one .....	60	resistance in .....	1101
2,3-Benzodiazepine-4-ones .....	61	selective COX-2 inhibitor for .....	828
Bisindoles .....	1154	sensitization to conventional therapies .....	827
effect on calmodulin-mediated functions .....	1154	small molecule inhibitors of protein kinases	
side-effect of .....	1155	in .....	1101
BMP inhibitors .....	1259	synthetic derivatives of isoflavone in .....	401
applications of .....	1259	taxanes/vincas for .....	885
Brain .....	1202	TGF- $\alpha$ inhibitors in .....	1258
effect of long-chain polyunsaturated fatty		therapy for .....	401
acids .....	1202	topoisomerase I/II inhibitors against .....	641
Breast cancer .....	990	Cancer biology .....	509
anti-metastatic activity of a bio-stable T140		preclinical findings of .....	509
analog against .....	990	TREG in .....	509
		Cancer cells .....	838
		function of ARBS in .....	838

Carbohydrate antigens .....	1357	<i>in vitro/in vivo</i> experiments .....	1313,1314
biological/clinical effects of .....	1360	molecular characteristics of .....	1312
cancer vaccines based on .....	1365	Clinical medicine .....	543
for diagnosis/immunotherapy .....	1360	Coagulation cascade .....	1111
immunological applications in cancer .....	1357	Colfarbine .....	575
preparation of tumor based .....	1361	administration of .....	576
synthesis aspects of .....	1357	mechanism of action of .....	575
tumor-associated .....	1357	pharmacokinetics of .....	576
Carbonic anhydrase inhibitors .....	922	Combinatorial chemistry .....	91
<i>N</i> -substituted sulfonamides as .....	922	in development of anti-HIV drugs .....	91
sulfamate motif in design of .....	924	role for integration .....	95
sulfamide motif in design of .....	927	role for nucleocapsid protein .....	96
urea/hydroxyurea as .....	923	role for protease inhibitors .....	99
Carbonic anhydrases .....	921	role for REV/TAT-TAR RNA interaction .....	96
Cardioprotection .....	1123	role for reverse transcription .....	94
altered gene expression in .....	1123	role for viral entry .....	92
CCR8 .....	464	Combinatorial synthesis .....	109
antagonists of .....	464	cyclization methods in .....	113
clinical investigation of .....	464	enolate-imine condensation in .....	112
in mouse asthma models .....	464	of bicyclic $\beta$ -lactams .....	116
Cellular Prion protein (PrP <sup>c</sup> ) .....	589	of monocyclic $\beta$ -lactams .....	109
Ceramide .....	699	Staudinger reaction in .....	109
effect of anti-apoptotic compounds .....	705	Constitutive androstane receptor (CAR) .....	937
effect on apoptosis .....	699,702	ligand recognition by drug-activated .....	937
effect on intrinsic apoptotic pathway .....	703	prediction of ligands for .....	941
effects on extrinsic apoptotic pathway .....	702	structural/site-directed mutagenesis/molecular	
in apoptotic diseases .....	699	modeling studies of .....	937
Chemicals .....	247	Corticosteroids .....	417
<i>in vitro</i> assays of .....	247	pharmacokinetic models of .....	417,421
<i>in vivo</i> assays using animals .....	248	pharmacokinetic profiles of .....	420
test systems to evaluate skin sensitizing		COX-2 inhibitors .....	1378
potency of .....	247	as anti-breast cancer .....	1380
Chemical-assemblies .....	793	as anti-cancer .....	1378
Chemical communication .....	817	as anti-colon cancer .....	1379
Chemokine .....	463,1016	as anti-neurological diseases .....	1380
inhibition of .....	1016	as anti-prostate cancer .....	1379
receptors for .....	463	CRH receptors .....	1120
Chemokine receptor CXCR4 .....	989	Cyclic <i>N</i> -acylphosphoramidite monomer .....	322
against pancreatic cancer .....	991	Cyclooctadiene .....	3
against small cell lung .....	991	ZED versions of .....	3
antagonists derived from T140 derivatives .....	990	Cyclooxygenase .....	827
anti-ALL/CLL activities of .....	992	genes of .....	827
anti-metastatic activity against melanoma .....	991	in cancer .....	827
anti-RA activity of a bio-stable T140 analog		in chemoprevention .....	827
of .....	992	structure of .....	827
as therapeutic for diseases .....	989	Cyclooxygenase 2 .....	1375
effects against multiple myeloma .....	991	as anti-glaucoma .....	1377
profiles of T140 analogs of .....	992	as anti-inflammation .....	1375
small-sized antagonists based on cyclic		function of .....	1375
pentapeptides .....	992	selective inhibitors of .....	1375
Chondroitin sulphate .....	1311	Cysteine proteinase inhibitors .....	1025
antioxidant activity of .....	1317	as therapy for parasitic diseases .....	1025
antioxidant properties of .....	1311	design of .....	1025
as metal ion chelator .....	1312	Cytosol .....	1075
beneficial effects of .....	1311	abnormal A $\beta$ 42 localization in .....	1075
human studies of .....	1316		

Diabetes .....	313	Ether lipids .....	533
cardiovascular disease in .....	313	Exogenous corticosteroids .....	424
inhibitors of AGE-RAGE system in .....	316	PK models for .....	425
role of AGEs in .....	315	Weibull model for .....	426
role of postrandial hyperglycemia in CVD in .....	313	Extracellular matrix (ECM) remodeling .....	1243
roles of RAS/inhibiting in CVD in .....	316		
1,4-Dihydropyridines .....	747	Factor Xa .....	859
as calcium modulatory compounds .....	747	determinants of specificity of .....	859
fused type .....	747	inhibition by TEPI .....	863
Dihydrorhodamine .....	309	inhibition by ZPI .....	861
oxidation of .....	309	interactions of .....	859
DNA/carrier complex .....	1289	physiological inhibitors of .....	859
methods to characterize .....	1289	Failing myocardium .....	785
DNQX .....	1194	calcium sensitizers for .....	786
preparation of .....	1194	hormones for .....	787
Drug discovery .....	1269,1299	natriuretic peptides for .....	787
antibacterials in .....	1304	phosphodiesterase inhibitors for .....	785
carbohydrate-based scaffolds in .....	1299	steroids for .....	789
endothelin receptor in .....	1305	thyroxin for .....	789
herbicides in .....	1305	Filarial infections .....	203
HIV-1 protease in .....	1306	antiwolbachial treatment of .....	208
integrins in .....	1304	biology of .....	203
LPA receptor in .....	1306	Fused benzodiazepine systems .....	62
MMP/TACE in .....	1306		
P-gp/MRP in .....	1307	$\alpha$ -GalCer .....	1251
RNA binders in .....	1307	immune modulatory activities of .....	1251
SH-2 Domain in .....	1307	Geminin .....	461
SST/NK receptors in .....	1302	as molecular target .....	461
Drug resistance .....	123	effect on cell cycle .....	461
functional cloning of .....	126	in cancer .....	461
mechanisms of .....	125	in development of anticancer drugs .....	461
model systems to study .....	125	structure of .....	461
		therapeutic potential of .....	462
Edelfosine .....	539	Gene delivery .....	1285
Electron spin resonance .....	211	cationic lipids for .....	1294
biological applications of .....	213	cationic polymers for .....	1289
in tropical parasitic diseases .....	211	dendrimers for .....	1292
Endocannabinoid .....	257	non-viral delivery vectors for .....	1289
degradation of .....	257	non-viral mediated .....	1285
therapeutic potential of .....	257	polysaccharides for .....	1294
Endogenous hydrocortisone .....	421	traversing to nucleus for .....	1288
chaotic models of .....	423	Genistein .....	331,401
gamma model of .....	424	action on signal transduction components .....	333
linear release rate model of .....	422	as natural isoflavonoid .....	331
PK models for .....	421,424	biological properties of .....	331,401
polynomial models of .....	421	clinical trials of .....	334
stochastic models of .....	424	effect on growth .....	331
trigonometric models of .....	421	effect on signaling of breast cancer cells .....	334
ERKS .....	695	effect on signaling pathways .....	331
inhibition of .....	695	<i>in vitro</i> anticancer effects of .....	334
inhibitors for .....	695	molecular mechanisms of action of .....	402
Estrogens .....	44,897	molecular structure of .....	401
effects of activation of receptors of .....	903	regulation of Akt pathway by .....	404
in cancer .....	901	regulation of AR pathway by .....	403
receptors for .....	44,902	regulation of expression of genes related to angiogenesis/metastasis by .....	405

regulation of MAPK pathway by .....	404	effect on immune responses .....	1020
regulation of NF- $\kappa$ B pathway by .....	404	inhibition of cell growth/angiogenic factors	
regulatory effects on estrogenicity .....	331	by .....	1018
structure of .....	331	inhibition of complement by .....	1019
$\beta$ -(1,3)-Glucans .....	1341	inhibition of leukocyte integrins by .....	1018
applications of .....	1341	inhibition of leukocyte transmigration by .....	1018
chemical approaches to .....	1345	structural requirements of .....	1009
chemo-enzymatic synthesis of .....	1346	Hepatitis C virus .....	527,1263
complement receptor 3 (CR3) for .....	1343	biologic inhibitors of .....	1266
immunomodulating type .....	1341	imidazoquinolines in .....	527
lactosylceramides/scavenger receptors for .....	1343	immune response in .....	527
receptors for .....	1341	non-nucleoside inhibitors for .....	1265
structure-activity relationships of .....	1343	novel immune response modifiers in .....	528
synthesis of .....	1344	NS5B RdRp for .....	1263
Glucocorticoids .....	417	nucleoside inhibitors for .....	1263
absorption of .....	418	role of biologic modulators .....	527
activities of .....	417	role of NS5B sequence variability .....	1267
distribution of .....	418	role of small molecule .....	527
elimination of .....	419	small molecule/biological inhibitors of .....	1263
metabolism of .....	419	TLR7 agonists in .....	528
pharmacokinetic models of .....	421	TLR9 agonists in .....	529
pharmacokinetics of .....	418	High throughput bioanalysis .....	1059
structures of .....	417	Histidine .....	223
synthesis of .....	417	CNS activity of .....	223
Glutamate receptor .....	1091	Histone deacetylases (HDACs) .....	515
agonist selectivity of .....	1092	antiproliferative activity of .....	523
in biological membranes for detection of		catalytic mechanism of .....	515
L-glutamate .....	1094	enzyme inhibitory activity of .....	518
Glycogen phosphorylase .....	845	three-dimensional structure of .....	515
active site inhibitors of .....	848	HIV entry .....	557
AMP site inhibitors of .....	849	effect of CCR5 antagonists .....	558
AMP site inhibitors of .....	853	effect of CD4 attachment inhibitors .....	557
azasugar inhibitors of .....	848	effect of co-receptor inhibitors .....	558
clinical results with inhibitors of .....	854	effect of CXCR4 antagonists .....	559
effects of inhibitors on gluconeogenesis .....	852	effect of drugs .....	557
genetics GP deficiency of .....	847	effect of viral fusion inhibitors .....	560
glycogen storage site inhibitors of .....	852	HIV-1 reverse transcriptase .....	549
<i>in vivo</i> effects of .....	853	molecular insights into .....	549
indole binding site inhibitors of .....	851	resistance to nucleoside analogs .....	549
indole site inhibitors of .....	854	HIV-1 RNase H .....	727
inhibitors of .....	845	as drug target .....	727
purine nucleoside site inhibitors of .....	852	function of .....	727
therapeutic applications of inhibitors of .....	855	inhibitors for .....	730
Glycolipids .....	1249	relationship with polymerase RT inhibitors	
as immune modulatory tools .....	1249	(RTI) .....	729
$\alpha$ -Glycolipids .....	1250	HIV-1 RT .....	728
as NKT ligands .....	1250	functional correlation of domains of .....	728
$\beta$ -Glycolipids .....	1252	structure of .....	728
NKT ligands .....	1252	Hsp90 inhibitors .....	1137
Glycosidase inhibitors .....	1043	as anti-cancer drugs .....	1137
Glycosylation pathways .....	1043	Human beta-defensin-3 .....	1063
as drug targets for cancer .....	1043	antimicrobial activity of .....	1066
Gram-positives .....	376	as antimicrobial peptide .....	1063
development of quinolone activity against .....	376	medical/clinical applications of .....	1069
HCV NS3 protease .....	984	modulation expression of .....	1065
Heparin .....	1009	proinflammatory activity of .....	1069
anti-inflammatory activities of .....	1009	structure of .....	1063
		tissue distribution of .....	1064

Human serum albumin (HAS) .....	483	Immuneparalysis .....	509
allosteric modulation of drug binding to .....	483	in cancer patients .....	509
based ligand recognition .....	483	Inflammatory bowel disease .....	771
based protein recognition .....	484	adalimumab for .....	775
biomedical aspects of .....	487	anti IL-12 for .....	778
structure activity relationships of .....	487	anti-adhesion molecules therapies for .....	776
Human tumors .....	681	anti-CD3 therapy for .....	781
AP23464 for .....	685	anti-CD4 therapy for .....	779
AZM475271/AZD0530 for .....	684	anti-ICAM-1 therapy for .....	777
BMS-354825 for .....	684	anti-IFN- $\gamma$ antibody for .....	779
novel ATP-competitive SRC family kinase		anti-inflammatory cytokines for .....	779
inhibitors for .....	683	anti-TNF- $\alpha$ therapies for .....	773
PD-180970/PD-166326 for .....	684	biological therapies for .....	771
SKI-606 for .....	685	CDP571 for .....	774
Hydrophilic carotenoid amphiphiles .....	953	CDP870 for .....	775
activity against aqueous-phase reactive		etanercept for .....	775
oxygen species (ROS) .....	962	generality on biology therapy in .....	772
aqueous aggregation/dispersibility of .....	960	growth factors for .....	779
astaxanthin-based derivatives of .....	955	immunomodulators for .....	780
biological applications of .....	953,962	immunostimulators for .....	778
cancer chemoprevention by .....	965	infiximab for .....	773
cardiovascular applications of .....	963	inhibitor of TH1 polarization for .....	778
design/synthesis of .....	955	inhibitors of proinflammatory cytokines	
in hepatitis .....	964	receptors for .....	780
in macular degeneration .....	966	inhibitors of T cells activation for .....	779
in prostate cancer .....	966	inhibitors of T cells proliferation for .....	780
lutein/zeaxanthin-based derivatives of .....	956	inhibitors of transcription factors for .....	780
lycophyll-based derivatives of .....	959	LDP-02 (MLN-02) for .....	777
methods of synthesis of .....	953	MAPK inhibitors for .....	781
plasma protein binding studies of .....	963	natalizumab for .....	776
synthesis of lutein/zeaxanthin derivatives of .....	958	onercept for .....	775
synthesis of lycophyll derivatives of .....	959	pathogenic bases of .....	771
Hydroxamate .....	28	Innate immune system .....	249
<i>O</i> -linking strategy for .....	29	chemical interaction with skin activates .....	249
on resin-bound intermediate .....	28	Inotropic pharmacologic strategies .....	785
synthetic applications of .....	29	targeting failing myocardium in newborn/ infant .....	785
Hyperglycemia .....	349	Integrins .....	985
treatment of .....	349	Ischemic heart disease .....	1351
Hypertension .....	494	low-dose aspirin in .....	1352
combination RAS blockade in .....	494	non-steroidal anti-inflammatory drugs in .....	1353
Ifosfamide .....	395	prothrombotic potential of NSAID in .....	1351
analogs of .....	395,397	selective COX-2 inhibitors in .....	1352
metabolic studies of .....	395	Ischemic injury .....	1081
metabolism of .....	395	Isoflavone .....	405
Imatinib .....	1101	biological activity of synthetic derivatives of .....	406
as prototype kinase inhibitory drug .....	1101	for inhibition of cancer .....	405
Imiquimod (IM) .....	499	novel synthetic derivatives of .....	405
by topical route .....	499	synthesis/molecular characterization of	
clinical applications of .....	499,501	derivatives of .....	405
mechanism of action of .....	499,501	Japanese traditional herbal medicine .....	543
Immucillin-H .....	578	reconsideration of .....	543
administration of .....	579	research of .....	543
clinical observations of .....	580	JNK .....	690
mechanism of action of .....	578	inhibitors of .....	690
pharmacokinetics of .....	579	K65R .....	553
Immune responses .....	247		

Kahalalide A .....	9	ginseng in .....	546
solid-phase total synthesis of .....	9	Hange-Shashin-To as .....	546
Kinesin inhibitors .....	888	In-Yang theory of .....	544
Kupffer cells .....	1327	Ki-Ketsu-Sui theory of .....	544
as targets for modulation of liver		Onji as .....	545
inflammation/oxidative stress .....	1327	Oren-Gedoku-To as .....	546
		philosophy of .....	544
		scientific approach to .....	544
		Sho-Saiko-To as .....	544
		Syakuyaku-Kanzo-to as .....	545
		theory of .....	544
		Yoku-Kan-San as .....	546
L74V .....	553	Matrix metalloproteinase (MMP) .....	1243
Lactam compounds .....	109	substrate relationships of .....	1243
combinatorial synthesis of .....	109	targets to block activity of .....	1243
liquid-phase combinatorial synthesis of .....	117	inhibitor design for .....	1243
polymer-supported synthesis of .....	109	selective inhibitors for .....	1244
sequential column asymmetric catalysis of .....	118	novel proteomic strategies to .....	1245
Leishmania genes .....	123	MC4R .....	981
functional cloning to identify .....	123	MDM2 .....	983
in drug resistance .....	123	Medicinal chemistry .....	1217
Leishmaniases .....	145	computational scaffold abstractions in .....	1218
development of miltefosine for .....	145	FEPOPS in .....	1226
mechanisms of action of .....	149	hopping in .....	1217
new formulations/derivatives of amphotericin		ligand-based scaffold hopping in .....	1220
B for treatment of .....	153	molecular scaffolds in .....	1217
Leptin .....	897	scaffolds in .....	1217
in lipid oxidation .....	899	Medicinal plants .....	611
intracellular pathways of action of .....	898	as sources of lead compounds .....	611
receptors for .....	897	with anti-coagulant activity .....	622
Leukocyte .....	1009	with anti-platelet activity .....	613
extravasation of .....	1009	with anti-platelet/anti-coagulant activities .....	611
L-glutamate .....	1091	Melanoma .....	387
Gluox immobilized for .....	1095	AKT3 in .....	389
Gluox-based membranes for imaging of .....	1095	failure of chemotherapy in .....	387
Glur channels in planar BLMS for sensing of .....	1091	inhibit multiple pathways in .....	391
medical sensing of .....	1091	NFκB in .....	390
receptors/enzymes for .....	1091	P13K in .....	389
Ligand-based scaffold hopping .....	1222	proteasome in .....	391
molecular descriptors for .....	1222	role of Bcr-abl .....	387
Lipid peroxidation .....	309	targeted therapy of .....	387
Lipoic acid .....	1269	Metabolic syndrome .....	563
as multi-target-directed compounds .....	1270	partial agonists/antagonists in .....	568
for multi-target-directed drugs .....	1269	PPAR ligands for .....	563
for neurodegeneration .....	1269	Metabolism .....	1055
Liver inflammation .....	1321	Microcystin .....	279
arachidonic acid cascade in .....	1321	effects of high doses on cells <i>in vitro</i> .....	281
cytokines in .....	1325	effects on liver cells in dose dependent	
growth factors in .....	1325	manner .....	279
5-lipoxygenase (5-LO) pathway in .....	1323	molecular mechanisms of PP-inhibition by .....	280
regulation of .....	1321	proliferative effects of trace doses of .....	283
Malaria .....	1231	toxicity in multi-cellular organisms .....	279
prevention of eIF-5A formation for .....	1237	Microtubules .....	1147
Malarial parasites .....	166	interference with polymerization/	
redox-active proteins for .....	166	depolymerization of .....	1147
MAMPO .....	543	Miltefosine .....	145
characteristics of .....	543	development for cutaneous leishmaniasis .....	148
concept of .....	543	development for visceral leishmaniasis .....	147
diagnosis by .....	544		

efficacy against leishmania .....	145	Nelarabine .....	577
efficacy against related protozoa .....	146	administration of .....	578
for cancer .....	145	clinical observations of .....	578
preclinical development for leishmaniases .....	145	mechanism of action of .....	577
Mitochondria-mediated apoptosis .....	281	pharmacokinetics of .....	578
<i>via</i> classic BID-BAX-BCL-2 pathway .....	281	Neoplasia .....	828
Mitogen-activated protein kinase .....	689	NSAIDs for .....	828
Mitotic inhibitors .....	885	Neuraminidase (NA) .....	429
aurora kinase inhibitors for .....	889	function of .....	430
for cancer treatment .....	885	structure of .....	430
kinesin motor inhibitors for .....	887	Neuraminidase inhibitors .....	432
microtubule inhibitors for .....	885	based on sialic acid .....	432
Molecular descriptors .....	450	containing cyclopentane scaffold .....	440
Molecular scaffolds .....	1218	containing pyrrolidine scaffold .....	442
in medicinal chemistry .....	1218	containing benzoic acid scaffold .....	435
Molecular symmetry .....	639	containing cyclohexene scaffold .....	438
as structural property .....	639	development of .....	432
effect of apoptosis .....	645	resistance of influenza viruses to .....	445
effect on cytotoxicity .....	640	Neuroactive compounds .....	997
in curcumin analogs .....	646	batrachotoxin as .....	1001
in cytotoxic/proapoptotic drugs .....	639	brevetoxin as .....	1001
in drugs that target proteins .....	644	capsaicin as .....	1003
in metal complexes .....	645	cocaine as .....	998
Multi drug resistance .....	1383	curare as .....	999
calmodulin antagonists as reversers of .....	1386	derived from Latin America .....	997
in cancer cells .....	1383	discovery/development of .....	1005
targeting calmodulin in reversing .....	1383	epibatidine as .....	1001
Multimodality imaging .....	227	historical/current perspectives of .....	997
of tumor integrin $\alpha_v\beta_3$ expression .....	227	histrionicotoxin as .....	1000
Muscular disorders .....	1258	mescaline/ <i>N,N</i> -dimethyl tryptamine as .....	1001
myostatin inhibitors in .....	1258	non-peptidergic .....	998
Myostatin .....	765	peptidergic based .....	1004
antagonism in muscle dystrophy .....	768	pumiliotoxins as .....	999
biology of .....	765	quinine as .....	1000
clinical relevance of .....	765	Neurogenesis .....	667
in adipose tissue .....	767	Neurological disorders .....	1203
in muscle .....	766	long-chain polyunsaturated fatty acids in .....	1203
in rhabdomyosarcoma cells .....	767	Neurons .....	1075
processing/signaling pathway of .....	765	Neuroprotective factors .....	875
NAD kinase .....	739	discovery of .....	875
bacterial NAD kinase as .....	740	for development of therapeutics .....	881
enzymatic properties of .....	740	in hypocoagulation .....	880
human NAD kinase as .....	743	in immunosuppression .....	881
in NADP biosynthesis .....	739	in serum/tissue from hibernating species .....	875
structural properties of .....	743	protective mechanisms in hibernating species .....	881
structural/functional properties of .....	739	protective mechanisms in hibernating animals .....	876
regulated by .....	876	NF- $\kappa$ B inhibitors .....	945
<i>N</i> -Alkyl hydroxamic acids .....	31	lignans as .....	949
synthesis of .....	31	naturally occurring .....	945
synthetic applications of .....	33	terpenoids as .....	947
Natural coumarins .....	265	Nickel-protein interactions .....	251
as antioxidants .....	265	proteomic analysis of .....	251
role in cytotoxicity .....	271	NKT cells .....	1250
Natural products .....	349	in immune responses .....	1250
anti-hyperglycemic potential of .....	349	ligands for .....	1250
total solid-phase synthesis of analogs from .....	15	microbial CD1D-presented lipid activators of .....	1250

NMDA receptor .....	805	Parasites .....	131
amino-terminal domain at .....	812	inhibitors from plants .....	135
channel pore at .....	809	treatment/control of .....	132
clinical considerations of .....	813	Peptide structures .....	979
excito-toxicity by .....	805	for unlocking challenging targets .....	979
glutamate binding pocket at .....	807	Peroxisome proliferator-activated receptors (PPARs) .....	357
in design of neuroprotective therapies .....	805	in cardiac hypertrophy .....	357
structural properties of .....	805	in energy metabolism .....	360
structure of .....	805	ligands of .....	358
Non-alcoholic fatty liver disease .....	653	mechanisms of action of .....	358
pathophysiological liver disease .....	653	tissue distribution of .....	358
Non-ATP competitive kinase inhibitors .....	711	to control of fatty acid oxidation .....	357
Non-ATP competitive small-molecule inhibitors .....	711	PET imaging .....	229
ATP versus .....	711	of tumor integrin $\alpha_v\beta_3$ .....	229
development of .....	711	Pharmacophore .....	658
mechanisms of .....	714	applications of .....	662
of protein kinases .....	711	elements of selective inhibitors .....	660
Non-excitable cells .....	409	from molecular modeling/SAR .....	658
calcium signaling in .....	409	influence of biology/X-ray crystallography on .....	659
reactive oxygen species in .....	409	refinements to .....	659
Non-hydroxamate histone deacetylase inhibitors .....	515	role of designer analogues .....	661
mechanism-based drug design of .....	517	with molecular modeling .....	660
molecular design of .....	516	Phosphorothioates .....	319
rational design of .....	515	chirality of .....	319
structure-based drug design of .....	516	PIK inhibitors .....	893
Non-phosphorus cationic glycerolipids .....	533	Plant-derived phenols/polyphenols .....	946
effect on tumor cells with overexpressed lipid .....	541	effect on NF-KB system .....	946
microdomains .....	541	Plaque instability .....	315
SAR of .....	534	role of AGEs in .....	315
synthesis of .....	534	Plasma membrane calcium pump .....	583
Non-steroidal anti-inflammatory drugs (NSAID) .....	1351	as novel therapeutic target for heart disease .....	583
Optically pure $\beta$ -amino acids .....	293	in signaling .....	586
role in small peptides .....	293	inhibitors of .....	586
Organ preservation .....	1081	PDZ interaction of .....	584
cation ratios in .....	1083	regulation of cell growth by .....	586
colloids/impermeants in .....	1084	regulation of NNOS by .....	586
energy depletion in .....	1084	structure of .....	583
pH buffering in .....	1084	subcellular localization of .....	584
principles of .....	1081	<i>Plasmodium</i> .....	1231
rinse solutions in .....	1087	genes in hypusine biosynthesis in .....	1235
Oxazaphosphorines incorporating heterocycles .....	327	inhibition of hypusine biosynthesis in .....	1231
Oxidative stress .....	1269,1321	polyamine pathway in .....	1231
arachidonic acid cascade in .....	1321	strategy in prevention/therapy of .....	1231
cytokines in .....	1325	<i>Plasmodium falciparum</i> .....	177
growth factors in .....	1325	drug targets for .....	177
lipoic acid in .....	1269	Platelet aggregation inhibitors .....	467
5-lipoxygenase (5-LO) pathway in .....	1323	QSAR study on .....	467
regulation of .....	1321	PNQX .....	1194
p38 Kinase .....	692	preparation of .....	1194
inhibitors of .....	692	Polycationic carriers .....	1285
P38 MAPK .....	869	for gene delivery .....	1285
downstream effects of .....	869	structure/design of .....	1285
inhibitors for .....	870	Polyunsaturated fatty acids .....	1201
Papain-like cysteine proteinases .....	1025	in Alzheimer's diseases .....	1204
of protozoan parasites .....	1025	in depression .....	1206
		in multiple sclerosis .....	1208

in neurological diseases .....	1201	Proteomics .....	241
in Parkinson's disease .....	1208	in medicinal chemistry .....	241
in psychiatry .....	1206	Protozoan diseases .....	1025
Postprandial hyperglycemia .....	314	affinity labels against .....	1030
inhibitors of .....	314	dipeptidyl compounds against .....	1026
Post-synthetic transformation .....	27	nitric oxide-donors against .....	1029
form carboxylate .....	27	non-peptidyl compounds against .....	1027
PP1/PP2A inhibitors .....	657	Purine nucleoside analogs .....	575
PPAR agonists .....	563	as anticancer agents .....	575
in treatment of type 2 diabetes .....	563	clofarabine as .....	575
Pregnane X receptor .....	937	pharmacological/clinical studies on .....	575
ligand recognition by drug-activated .....	937	PXR/CAR ligand-binding domains .....	937
prediction of ligands for .....	941	properties of .....	937
structural/site-directed mutagenesis/molecular .....		structures of .....	937
modeling studies of .....	937	Pyroglutamic acid .....	222
Prion protein .....	589	CNS activity of .....	223
characteristics of .....	589	Quinazoline-2,4-diones .....	625
functions of .....	589	analogues of .....	625
prevention of apoptosis by .....	593	from resin-bound compounds with primary .....	
structure of .....	589	amines .....	625
study by gene targeting method .....	591	solid-phase synthesis of .....	625
to prevents apoptosis in prp-deficient cell lines .....	597	Quinolones .....	375
using knockout mice/derived cell lines .....	589	antibacterial activity against gram-positive .....	
Pro-drug formats .....	793	bacteria .....	375
Programmed cell death machinery .....	1033	structure-activity relationships of .....	375,378
anti-tumor therapeutic molecules to target .....	1033	Quinoxaline-2,3-dione AMPA/GLYN receptor .....	
Prolineamide .....	223	antagonist .....	1184
CNS activity of .....	223	Quinoxalinones .....	1179
Prostaglandins .....	827	anticancer activity of .....	1182
Prostate cancer .....	835	antimicrobial activities of .....	1179
ANG-II in .....	840	antithrombotic activity of .....	1180
angiotensin in .....	840	biological properties of .....	1179
angiotensin II receptor in .....	837	chemistry of .....	1179,1190
antitumor agent for .....	835	deconditioning activity of .....	1180
AT1 receptor for .....	838	dipeptidyl peptidase-IV (DPP-IV) inhibition .....	
AT2 receptor for .....	838	by .....	1180
AT4 receptor for .....	838	preparations of .....	1190
classical renin-angiotensin system (RAS) in .....	836	reactions of .....	1193
cytokinesin in .....	836	SAR analysis of .....	1179
growth factors in .....	836	Quorum sensing (QS) .....	817
hormonal therapy for .....	841	AHL analogs as agonists of .....	818
local RAS in .....	837	antagonists of .....	819
microenvironment of .....	841	synthetic compounds of .....	818
oxidative stress in .....	840	Reactive oxygen species (ROS) .....	409
role of androgen receptor in development/ .....		in calcium homeostasis .....	409
progression of .....	835	Recombinant factor VIIA .....	1111
Proteins .....	247	adverse effects of .....	1116
antigenic T cell determinants by .....	249	antigenicity of .....	1116
interactions of chemicals/metal ions with .....	247	clinical properties of .....	1111,1115
Protein kinase C .....	702	in tissue factor pathway of coagulation .....	1111
modulation of signaling cascades by .....	702	initial clinical use of .....	1111
Proteinuric kidney diseases .....	495	monitoring therapy of .....	1115
combination RAS blockade in .....	495	preparation of .....	1114
Proteomes .....	241	structure of .....	1113
development of methodology for quantitative .....			
analyses of .....	241		

Redox-active enzymes .....	163	role of novel polymers/surfactants .....	798
for design of antimalarial drugs .....	163	role of pro-drug surface active molecules .....	798
interference with .....	163	synthesis of .....	793
Redox-active proteins .....	171	synthetic chemistry of .....	799
Regulatory T cells .....	509	Ser/thr protein phosphatase inhibitors .....	657
as target for biochemical therapies .....	509	pharmacophore identification of .....	657
biochemical strategies modulating .....	511	Sesquiterpene lactones .....	249
biology of .....	509	as allergens .....	249
effect of anti-CD25 monoclonal antibodies		as immuno-suppressants .....	249
(mAb) .....	511	Silicon switches .....	1169
effect of cyclophosphamide .....	511	examples of .....	1170
effect of denileukin [DAB(486) IL-2 .....	511	of marketed drugs .....	1169
effect of fludarabine .....	511	technology of .....	1169
in cancer biology .....	509	S-layer proteins .....	909
in human cancer .....	510	based lipid chips .....	915
siRNA targeting FoxP3 .....	511	chemical properties/molecular biology of .....	911
Renin-angiotensin system .....	491	in molecular construction kit .....	909
safety of combination blockade of .....	496	molecular construction kit based on .....	912
Reperfusion injury .....	1082	on liposomes as model for target systems .....	915
RGD-4C .....	759	role in biomedical nanotechnology .....	909
targeting of .....	759	self-assembly properties of .....	910
Rheumatoid arthritis .....	867	structural analysis of .....	910
identification of .....	869	Small molecular weight inhibitors .....	689
p38 MAPK inhibitors in animal models for .....	871	of stress-activated/mitogen-activated protein	
p38 MAPK pathway in .....	868	kinases .....	689
p38 mitogen-activated protein kinase		Small molecule effectors .....	971
(MAPK) in .....	867	modulation of catalytic RNA biological	
pathogenesis of .....	867	activity by .....	971
signal transduction pathways in .....	868	Small RNA ligands .....	971
therapy for .....	867	effect on RI-RI-bozymes/RNase P .....	975
Rho-kinase .....	339	effect on ribosome .....	972
as drug target .....	339	Solid organ transplantation .....	1081
effect on airway smooth muscle contraction .....	342	preservation solutions for .....	1081
effect on smooth muscle specific gene		Solid tumors .....	577
transcription .....	343	clinical trials of .....	576
for treatment of airway hyperresponsiveness		in acute leukemias .....	576
in asthma .....	339	in myelodysplastic syndromes (MDS) .....	576
regulation of signaling .....	341	Solid-phase combinatorial synthetic strategies .....	53,71
Rho-kinase inhibitors .....	341	for banzimidazolones .....	83
fasudil (HA-1077)/analogues as .....	341	for benzimidazoles .....	81
pharmacology of .....	341	for benzodiazepine based privileged structures .....	53
Y-27632/analogues as .....	341	for benzothiadiazinone .....	79
Ribozymes .....	971	for cinnolines/phthalazines .....	80
Scaffolds .....	1299	for fused quinoxalines/quinazolines .....	80
carbohydrates as .....	1299	for indazoles .....	86
Selectin .....	1011	for pyranobenzimidazoles .....	85
inhibition of .....	1011	for quinazolindiones .....	78
Self-assembling drug conjugates .....	793	for quinazoline .....	74
characterization of .....	793	for quinazolinones .....	77
drug monitoring/delivery of .....	801	for quinoxaline/quinazoline/benzimidazole	
for targeted medicinal application .....	793	based privileged structures .....	70
<i>in vitro</i> modeling of .....	793	for quinoxalinones .....	72
post-platform technology modifications/		for thiobenzimidazoles .....	84
designer engineering for .....	801	for thioxoquinazolinone .....	79
role of colloids .....	795	for triazabenzoozulenone .....	85
role of nano-assemblies .....	798	for triazinobenzimidazolediones .....	85
		Solid-phase guanidine synthesis .....	3
		polymer-supported reagents in .....	3

Solid-phase <i>N</i> -acyliminium Pictet-Spengler reactions .....	7	of enantiomerically pure $\beta$ -amino acids .....	295
Solid-phase organic synthesis (SPOS) .....	37	of enantiomerically pure aziridines .....	299
of $17\beta$ -hydroxysteroid dehydrogenases .....	40	of pyrrolobenzodiazepines .....	66
of modulators of estrogenic/androgenic action .....	37	of $\alpha$ -substituted- $\beta$ -amino acids .....	293
of type 1 $17\beta$ -HSD .....	42	Synthetic coumarins .....	265
of type 3 $17\beta$ -HSD .....	42	role in cytotoxicity .....	271
Solid-phase synthesis .....	3,27,626	Synthons .....	321
of 1,2,4-benzothiadiazin-3-one 1,1-dioxides .....	631	bicyclic oxazaphospholidine as .....	321
of 2,1,3-benzothiadiazin-4-one .....	630	Systems biology .....	1275
of 2-alkoxyquinazolin-4-ones .....	629	anti-bacterial drug discovery using .....	1275
of 2-alkyl/aryl quinazolin-4-ones .....	628	of <i>Plasmodium falciparum</i> .....	1278
of 2-aminoquinazolin-4-ones .....	629	Targeted therapy .....	387
of hydroxamic acid moiety .....	27	TGF- $\beta$ superfamily .....	1255
of quinazoline-2,4-dione analogues .....	630	binding proteins for .....	1256
of quinazoline-2,4-diones .....	626	clinical applications of .....	1255
of quinazoline-2-thioxo-4-ones .....	630	inhibitors of .....	1255
<i>N</i> -linking strategy for .....	31	small chemical inhibitors of .....	1258
polymer-supported reagents in .....	3	Thyrotropin-releasing hormone .....	221
Sphingolipids .....	671	analogs of .....	221
as targets for microbial infections .....	671	antagonists of .....	225
pathway in bacteria/viruses .....	676	CNS activity of .....	223
pathway in FUNGI .....	674	hormonal activity of .....	222
pathway in mammals .....	671	subtype-selective ligands of .....	225
pathways of protozoa .....	675	TLR9 inhibitor .....	289
Spin trapping .....	211	in rheumatoid arthritis .....	289
biological applications of .....	213	in systemic lupus erythematosus .....	289
in tropical parasitic diseases .....	211	Toll-like receptor 9 .....	287
Src family kinases .....	681	in A/D class CPG-ODN .....	287
in human tumor cells .....	683	in allergy .....	287
regulation of .....	681	in asthma .....	287
structure of .....	681	signaling for therapeutic use .....	287
Src inhibitors .....	681	Triazadibenzoazulenone .....	65
as therapeutic agents for human cancers .....	681	Triflate-like solid-phase multifunctional linker .....	6
PP1/PP2 as .....	683	Tumor angiogenesis .....	227
Statins .....	505	anatomical/functional imaging of .....	227
antioxidative actions of .....	505	Tumor integrin expression .....	228
chemical structure of .....	505	molecular imaging of .....	228
clinical study-regression of carotid atheroma by .....	505	Tumor-targeted peptides .....	757
<i>in vitro</i> study of .....	505	CD13 targeting by .....	760
mechanisms for antiatherosclerotic effects .....	505	for delivering therapeutic genes/chemical drugs .....	757
Statistical methods .....	449	function/molecular mechanism of .....	757
C4.5 decision tree (C4.5 DT) as .....	452	lymphatic vessel targeting by .....	761
<i>k</i> nearest neighbor (kNN) as .....	452	matrix-metalloprotease targeting by .....	760
linear discriminant analysis (LDA) as .....	452	VEGFR targeting by .....	761
logistic regression (LR) as .....	452	Type 2 diabetes .....	563
prediction of compounds .....	449	partial agonists/antagonists in .....	568
probabilistic neural network (PNN) as .....	452	PPAR ligands for .....	563
support vector machine (SVM) as .....	452	PPAR $\alpha$ / $\gamma$ agonists in .....	565
to study pharmacodynamic .....	449	PPAR $\delta$ /PAN agonist in .....	567
to study pharmacokinetic .....	449	Unusual amino acids .....	293
to study toxicological property .....	449	in naturally occurring peptides/biologically active analogues .....	293
Steroid sulfatase .....	37	synthesis of .....	293
Steroidogenic enzymes .....	44		
Stress-activated protein kinase .....	689		
Synthesis .....	28,66,293		
from polymer-supported hydroxylamine .....	28		

Urocortins .....	1119	as targets for novel chemotherapy against	
cardioprotection by .....	1119	filariasis .....	205
kinase pathways in cardioprotective effects		in adverse reactions to antimicrofilaricidal	
of .....	1122	treatment .....	207
therapeutic potential of .....	1119	role in biology of filarial worms .....	205
V75T .....	552	X4-HIV-1 entry .....	989
Vascular endothelial growth factor .....	667	discover of selective inhibitors against .....	989
in adult brain .....	667	Xylose-derived oxazaphosphorinanes .....	326
in neurogenesis .....	667		
Virtual screening .....	1159	YM-90K .....	1194
data-fusion vs. data aggregation in .....	1163	preparation of .....	1194
ligand-based .....	1160		
pre-filtering corporate collections in .....	1163	Zinc binding motifs .....	921
structure-based .....	1159	in design of selective carbonic anhydrase	
		inhibitors .....	921
Wolbachia endosymbionts .....	203		
as antibiotics target .....	203		
as sources of pathology .....	206		